• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Can Genotype-Guided Dosing Decrease Warfarin Complications?

image_pdfFavoriteLoadingFavorite

INTRODUCTION: 

  • Warfarin is the primary cause of medication-related emergency visits in older patients 
  • Differences in SNPs can impact metabolism of warfarin and consequent dose requirements  
  • Previous studies are inconclusive as to benefits of genotype-guided dosing  
  • Gage et al. (JAMA, 2017) sought to determine whether genotype-guided warfarin dosing improves the safety of warfarin administration 

METHODS: 

  • Double-blind randomized clinical trial (RCT) 
  • Patients aged 65 years or older initiating warfarin for elective hip or knee arthroplasty  
  • Patients were genotyped for DNA polymorphisms related to warfarin metabolism 
    • VKORC1-1639G>A, CYP2C9*2, CYP2C9*3, and CYP4F2 V433M 
  • Patients were randomized into: 
    • Genotype-guided warfarin dosing on day 1 through 11 
    • Clinically-guided warfarin dosing on day 1 through 11 
  • Patients also received a target INR of either 1.8 or 2.5 
  • Primary outcome was the composite of major bleeding, INR ≥ 4, VTE, or death 

RESULTS: 

  • 1650 patients were randomized 
    • 63.6% were female 
    • 91.0% were white  
    • Mean age 72.1 years (SD 5.4) 
  • 1597 (96.8%) completed the trial  
    • N= 808 in genotype-guided group  
    • N= 789 in clinically guided group 
  • In the genotype group there were fewer cases of  
    • Major bleeding (2 vs 8); Relative risk [RR], 0.24; 95%CI, 0.05-1.15 
    • INR ≥ 4 (56 vs 77) RR, 0.71; 95%CI, 0.51-0.99 
    • Venous thromboembolism (33 vs 38) RR, 0.85; 95%CI, 0.54-1.34 
  • There were no deaths 
  • When looking at a composite of the above adverse events 
    • Fewer patients in the genotype group (10.8%) met at least one of the adverse event end points compared to the clinical (14.7%)  
    • Absolute difference, 3.9% (95%CI, 0.7%-7.2%, P = .02) 
    • RR 0.73 (95%CI, 0.56-0.95) 

CONCLUSION: 

  • Among patients ≥ 65 undergoing elective hip or knee arthroplasty and treated with perioperative warfarin, genotype-guided warfarin dosing significantly reduced composite serious adverse events  
  • The main driver for reducing the composite adverse outcomes was INR ≥ 4 
  • Genotyping may be more helpful at non-academic/low volume hospitals which may have higher adverse events  
  • Cost-effectiveness was not addressed in this study 

Learn More – Primary Sources: 

Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty 

 

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Abnormal Vaginal Bleeding and Oral Anticoagulants for DVT – Results from the AMPLIFY trial
How Common is Venous Thromboembolism During Neoadjuvant Treatment for Ovarian Cancer?
When to Stop Anticoagulation Following a DVT or Pulmonary Embolus?
What Are the Risk Factors For Septic Pelvic Thrombophlebitis?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site